While pharma companies currently send many of the same IT activities, like software maintenance and desk support, offshore as other industries, Forrester's Business Technographics data shows that within the next 12 months, drug firms plan to increase the amount of custom app development done abroad. Pharma firms are feeling the dual pressure to satisfy the complex and costly demands of scientific discovery while keeping margin-focused stockholders happy. The fix? Pharma executives should step up their evaluation of offshore partners, particularly those in geographic proximity to their own global operations, to outsource IT-specific activities.
This is an excerpt
Buy Risk-Free
Price: US $499
Our Service Guarantee: If you are not completely satisfied with this document, notify Forrester within 24 hours of purchase for a full refund.
Already a Forrester Client? Log in to read this document.